Search results for "IMMUNOADSORPTION"

showing 8 items of 8 documents

Immunoadsorption for treatment of severe atopic dermatitis.

2017

Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Atopy is common in patients with AD and many patients have high levels of Immunoglobulin E (IgE), some of which recognizes exogenous or auto/self-allergens. Treatment options targeting IgE such as specific immunotherapy against e.g. house dust mites or using anti-IgE antibodies (omalizumab) showed variable results that …

0301 basic medicinemedicine.medical_specialtyPopulationOmalizumabDiseaseImmunoglobulin ESeverity of Illness IndexDermatitis AtopicAtopy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal MedicinemedicineGenetic predispositionHumanseducationImmunoadsorptionImmunosorbent Techniqueseducation.field_of_studybiologybusiness.industryGeneral MedicineAtopic dermatitisImmunoglobulin Emedicine.diseaseDermatologyUp-Regulation030104 developmental biologyTreatment OutcomeImmunologybiology.proteinCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugAtherosclerosis. Supplements
researchProduct

Protein�A immunoadsorption therapy for refractory, mitomycin�C?associated thrombotic microangiopathy

2007

BACKGROUND: Mitomycin C–associated thrombotic microangiopathy (TMA) has a poor prognosis with limited therapeutic options. Most patients die within 4 months of diagnosis due to pulmonary or renal failure. Here, a patient resistant to total plasma exchange (TPE) and immunosuppressive therapy with glucocorticoids, rituximab, vincristine, and splenectomy who was successfully treated with protein A immunoadsorption is described. CASE REPORT: A 29-year-old woman developed a TMA after chemotherapy with mitomycin C. She presented with thrombocytopenia, pulmonary edema, hemolytic anemia with presence of schistocytes, and renal failure. Immediate TPE (>120 times) and immunosuppressive therapy with g…

AdultHemolytic anemiamedicine.medical_specialtyThrombotic microangiopathyMitomycinmedicine.medical_treatmentImmunologySplenectomyGastroenterologyInternal medicinemedicineHumansImmunology and AllergyStaphylococcal Protein AImmunoadsorptionImmunosorbent TechniquesSalvage TherapyChemotherapyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionHematologymedicine.diseaseSurgerySchistocyteTreatment OutcomeHemolytic-Uremic SyndromeFemaleRituximabbusinessmedicine.drugTransfusion
researchProduct

Anaphylaktischer Schock nach Lipid-Austauschchromatographie bei einer Patientin mit angeborenem IgA-Mangel

1995

We report on a 59-year-old woman patient with selective IgA deficiency and familial hypercholesterinaemia. To lower elevated LDL levels in the patient's blood, immunoadsorption therapy with sheep-anti-human polyclonal antibodies coupled to sepharose columns was administered. During the procedure, the patient developed an anaphylactic shock requiring intensive care treatment. The patient's history revealed a fresh cell therapy with fetal sheep cells 10 years previously. Intracutaneous testing confirmed sensitization to sheep immunoglobulin, which was the most likely reason for the anaphylactic shock.

Allergybiologybusiness.industryDermatologySelective IgA deficiencyImmunoglobulin Emedicine.diseasemedicine.anatomical_structureImmunopathologyShock (circulatory)Immunologybiology.proteinmedicinemedicine.symptomAntibodyImmunoadsorptionbusinessSensitizationDer Hautarzt
researchProduct

The clinical impact of donor-specific antibodies in heart transplantation.

2018

Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection (AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac allograft vasculopathy (CAV). Anti-donor HLA antibodies are present in 3-11% of patients at the time of heart transplantation (HTx), with de novo DSA (predominantly anti-HLA class II) developing post-transplant in 10-30% of patients. DSA are associated with lower graft and patient survival after HTx, with one study suggesting a three-fold increase in mortality in patients who develop de novo DSA (dnDSA). DSA against anti-HLA class II, notably DQ, are at particularly high risk for graft loss. Although detection o…

OncologyGraft Rejectionmedicine.medical_specialty2747 Transplantationmedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology030230 surgeryAntibodies03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans10220 Clinic for SurgeryImmunoadsorptionKidney transplantationHeart transplantationTransplantationbiologybusiness.industryHazard ratioImmunosuppressionmedicine.disease10020 Clinic for Cardiac Surgerybody regionsbiology.proteinHeart TransplantationRituximabPlasmapheresisAntibodybusinessmedicine.drugTransplantation reviews (Orlando, Fla.)
researchProduct

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

2017

Background: Up to every fourth woman with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) suffers a clinically relevant relapse during pregnancy. High doses of steroids bear some serious risks, especially within the first trimester of pregnancy. Immunoadsorption (IA) is an effective and more selective treatment option in disabling MS relapse than plasma exchange. Data on the use of IA during pregnancy and breastfeeding are scarce. Methods: In this retrospective multicenter study, we analyzed the safety and efficacy of IA treatment in acute relapses during pregnancy or breastfeeding. The primary outcome parameter - change of acute relapse-related disability after IA…

Pediatricsmedicine.medical_specialtybreastfeedingBreastfeeding030204 cardiovascular system & hematologymultiple sclerosislcsh:RC346-42903 medical and health sciences0302 clinical medicineplasma exchangeHigh dosesMedicineIn patientSpectrum disorderImmunoadsorptionlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyrelapsePregnancytherapyNeuromyelitis opticabusiness.industryMultiple sclerosisneuromyelitis optica spectrum disordermedicine.diseaseeye diseasesNeurologyNeurology (clinical)pregnancybusiness030217 neurology & neurosurgeryimmunoadsorptionTherapeutic advances in neurological disorders
researchProduct

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

RegistrieMalePediatricsdiagnosismedicine.medical_treatmentHemostatic TechniqueKaplan-Meier EstimateregistryTHERAPYSettore MED/15 - Malattie Del SangueImmunosuppressive AgentIMMUNOADSORPTIONRisk FactorsPregnancy80 and overProspective StudiesRegistriesProspective cohort studyhealth care economics and organizationsAged 80 and overtreatmentImmunosuppressionHematologyMiddle AgedFACTOR-VIII INHIBITORAcquired hemophilia; Demographics; Diagnosis; Outcome; Registry; Treatment; Aged; Aged 80 and over; Autoantibodies; Chi-Square Distribution; Europe; Factor VIII; Female; Hemostatic Techniques; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pregnancy; Prospective Studies; Registries; Risk Assessment; Risk Factors; Treatment Outcome; Hemophilia A; HemorrhageAutoantibodieEuropeTreatment Outcomeacquired hemophilia; demographics; diagnosis; outcome; registry; treatmentoutcomeINTRAVENOUS GAMMA-GLOBULINFemaleacquired hemophiliaImmunosuppressive AgentsHumanmedicine.medical_specialtyHemorrhageHemophilia AMalignancyRisk Assessmenthemophilia registrydemographicsmedicineHumansMETAANALYSISAutoantibodiesAgedAutoimmune diseasePregnancyChi-Square DistributionFactor VIIIHemostatic Techniquesbusiness.industryRisk FactorAutoantibodymedicine.diseaseSurgeryProspective StudieHemostasisbusinessChi-squared distributionJournal of Thrombosis and Haemostasis
researchProduct

Prolonged Response of Chronic Immune Thrombocytopenic Purpura (ITP) to Extracorporeal Immunoadsorption

2000

business.industry030232 urology & nephrologyBiomedical EngineeringMedicine (miscellaneous)BioengineeringGeneral MedicineExtracorporeal immunoadsorption030204 cardiovascular system & hematologymedicine.diseaseThrombocytopenic purpuraBiomaterials03 medical and health sciences0302 clinical medicineImmune systemImmunologymedicinebusinessThe International Journal of Artificial Organs
researchProduct

Immunoadsorption with tryptophan columns: A therapeutic option for the treatment of rheumatoid arthritis with septic complications

2009

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting multiple organs and tissues. Although there is a wide range of therapeutic applications, the coexistence of severe side effects and contraindications outlines the necessity of new therapeutic options in the treatment of severe RA. We report on the case of a 71-year-old patient with successful treatment of a complicated RA with tryptophan immunoadsorption combined with low-dose steroids. Bacterial spondylitis developed in this patient during long-term treatment with infliximab and methotrexate. Weekly immunoadsorption sessions with tryptophan columns resulted in continuous suppression of RA activity over a perio…

medicine.medical_specialtyVisual analogue scaleGastroenterologyArthritis RheumatoidRefractorySepsisInternal medicineHumansMedicineImmunoadsorptionSpondylitisImmunosorbent TechniquesAgedAutoimmune diseasebusiness.industryTryptophanBacterial InfectionsHematologyGeneral Medicinemedicine.diseaseInfliximabSurgeryTreatment OutcomeRheumatoid arthritisSteroidsMethotrexatebusinessSpondylitismedicine.drugJournal of Clinical Apheresis
researchProduct